0001104659-25-012200.txt : 20250212 0001104659-25-012200.hdr.sgml : 20250212 20250212162210 ACCESSION NUMBER: 0001104659-25-012200 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250211 FILED AS OF DATE: 20250212 DATE AS OF CHANGE: 20250212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carter Todd Alfred CENTRAL INDEX KEY: 0001944011 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37625 FILM NUMBER: 25615158 MAIL ADDRESS: STREET 1: C/O VOYAGER THERAPEUTICS, INC. STREET 2: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Voyager Therapeutics, Inc. CENTRAL INDEX KEY: 0001640266 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-259-5340 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 tm256369-4_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2025-02-11 0 0001640266 Voyager Therapeutics, Inc. VYGR 0001944011 Carter Todd Alfred C/O VOYAGER THERAPEUTICS, INC. 75 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Scientific Officer 0 Common Stock 2025-02-11 4 S 0 5413 4.45 D 81023 D Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2025. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $5.00, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. /s/ Scott MacDonald, as Attorney-in-Fact for Todd Alfred Carter 2025-02-12